Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study

INTRODUCTION: There are no disease-modifying treatments for Parkinson’s disease (PD). We undertook the first drug screen in PD patient tissue and idntified ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims of this trial are to determine safety and tolerability of UDCA i...

Descripción completa

Detalles Bibliográficos
Autores principales: Payne, Thomas, Sassani, Matilde, Buckley, Ellen, Moll, Sarah, Anton, Adriana, Appleby, Matthew, Maru, Seema, Taylor, Rosie, McNeill, Alisdair, Hoggard, N, Mazza, Claudia, Wilkinson, Iain D, Jenkins, Thomas, Foltynie, Thomas, Bandmann, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409998/
https://www.ncbi.nlm.nih.gov/pubmed/32759251
http://dx.doi.org/10.1136/bmjopen-2020-038911

Ejemplares similares

Ejemplares similares